Archive · 7 Sep 2026
Sudarshan Pharma Proposes 9.5% MedTherapy Stake to Pursue Global Growth
Sudarshan Pharma wants to buy a small part of a biotechnology company in the United States.
The proposed stake would be 9.5%.
The biotechnology company is working on CAR-T cell therapy, which is an advanced treatment area for cancer.
It is planning to develop technology in the United States and manufacture products in India.
Sudarshan Pharma believes this could help it expand into new healthcare businesses.
Company promoters Hemal Mehta and Sachin Mehta also plan to buy stakes.
Together, the company and promoters could own 12.5% if the proposals are completed.
The investment is not final yet because checks, agreements and regulatory approvals are still needed.
The company hopes to complete it by March 31, 2027.
Sudarshan Pharma Industries Limited’s Board approved a proposed 9.50% stake in US-based MedTherapy Biotechnology Inc.
The investment would give Sudarshan Pharma exposure to CAR-T cell therapy and the wider cell and gene therapy sector.
MedTherapy is developing a US-India platform combining CAR-T technology development with manufacturing infrastructure in India.
Promoters Hemal Mehta and Sachin Mehta separately propose acquiring 1.50% each, taking the combined proposed interest to 12.50%.
The transaction remains subject to due diligence, definitive agreements, approvals and overseas-investment regulations, with completion targeted by March 31, 2027.
- Who
- Sudarshan Pharma Industries Limited, MedTherapy Biotechnology Inc., and promoters Hemal Mehta and Sachin Mehta.
- What
- A proposed acquisition of a 9.50% stake in MedTherapy, with the promoters separately proposing 1.50% each.
- When
- The announcement was dated September 7; completion is targeted by March 31, 2027, subject to conditions.
- Where
- The investment involves a US-based biotechnology company, technology development in the United States and manufacturing infrastructure in India.
- Why
- Sudarshan Pharma aims to expand globally and enter advanced oncology, cell and gene therapy, and the CAR-T therapy segment.
Potential Strategic Benefits
Transaction Conditions and Uncertainty
Expansion into biotechnology
Potential Strategic Benefits
Sudarshan Pharma says the proposed investment could provide access to the US biotechnology market, advanced oncology, CAR-T therapy and innovation-led healthcare opportunities.
Transaction Conditions and Uncertainty
The investment remains proposed rather than completed and depends on due diligence, definitive agreements, applicable approvals and compliance with overseas-investment regulations.
US-India platform
Potential Strategic Benefits
The companies could combine US-based innovation with cost-efficient Indian manufacturing, alongside commercialisation, distribution and market-access capabilities.
Transaction Conditions and Uncertainty
The articles describe these benefits as potential opportunities; they do not establish that the platform or international scale has already been achieved.
- Proposed company stake
- 9.50% of MedTherapy Biotechnology Inc.
- Proposed promoter stakes
- Hemal Mehta and Sachin Mehta each propose acquiring 1.50%.
- Combined proposed interest
- 12.50% for Sudarshan Pharma and its two promoters.
- Business focus
- CAR-T cell therapy, cell and gene therapy, and contract development and manufacturing.
- Operating model
- Technology development in the United States and manufacturing infrastructure in India.
- Consideration
- Cash consideration denominated in US dollars.
- Target completion
- March 31, 2027, subject to applicable conditions.
- Transaction status
- Subject to legal, financial, commercial and technical due diligence, definitive agreements and approvals.